{"entity":{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","aka":["DURGA-5"],"tldr":"A phase 3 trial of Daratumumab, Dexamethasone, Isatuximab in multiple myeloma, run by AstraZeneca, now recruiting.","summary":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT is a phase 3 interventional study registered as NCT07764978 by AstraZeneca, with 750 participants planned, started 2026-06-26 and due to reach its primary completion in 2029-01-11. Interventions recorded: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide. Conditions listed: Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07764978","url":"https://clinicaltrials.gov/study/NCT07764978"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["daratumumab","dexamethasone","isatuximab","lenalidomide","bortezomib","cyclophosphamide"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07764978","phase":"3","setting":"Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)","sponsor":"AstraZeneca","participation":[{"nct":"NCT07764978","source":"https://clinicaltrials.gov/study/NCT07764978","fetchedAt":"2026-10-07T16:56:49.835Z","studySha256":"f5ef7c1e9a770719d6da064fa4e9d7156711e309d5d9a6acb43a43887631523e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-14","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":750,"enrolmentType":"ESTIMATED","siteCount":124,"recruitingSiteCount":1,"countries":["Australia","Brazil","Canada","Denmark","France","Germany","Italy","Japan","Poland","South Korea","Spain","Sweden","Taiwan","United Kingdom","United States"]}],"started":"2026-06-26","startedType":"actual","enrolled":750,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07764978/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}